Production of plasma-derived products to highest international quality standards: Kedrion technology for the new Moscow plant
Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations
Kedrion buys a production plant in Hungary from Teva Pharmaceutical Industries Ltd
Kedrion SpA has bought yesterday from Teva Pharmaceutical Industries Ltd (a leading global pharmaceutical company) 100% of the shares in Human Bioplazma Manufacturing and Trading Ltd, a company established under the Hungarian law and based in Gödöllo (Budapest). Kedrion thus acquires a manpower of 127 employees, a fractionation and production plant with a productive capacity
Kedrion stakes on “vertical integration”, two agreements signed to buy four plasma collection centres in the USA and Germany
Kedrion has recently finalised two important agreements for the purchase of four plasma collection centres, two in the United States (Florida and Alabama) and two in Germany (Bavaria). The agreement to buy the two US centres, Pensacola (Florida) and Mobile (Alabama), has been signed with Life Therapeutics, a leader in plasma collection for therapeutic and
New method for purifying plasma proteins used to treat Haemophilia A and von Willerbrand disease
Increased availability of Factor VIII and von Willebrand Factor (vWF) using a new chromatography method for purifying Factor VIII and vWF concentrates that can be transferred to an industrial scale: is the result achieved by researchers in Kedrion. This is a particularly effective technique which makes it possible to purify almost double the quantity of
Human plasminogen acknowledged as Orphan Drug
The European Commission, following the positive opinion of the European Medicines Agency (EMEA), has granted the designation of orphan drug to Human Plasminogen, made by Kedrion, in the form of eye drops used for the treatment of ligneous conjunctivitis. Ligneous conjunctivitis is a rare form of conjunctivitis which may lead to blindness and is characterized
EMAS registration for Kedrion: the company’s environmental policy reinforced
Kedrion SpA, specialized in the production of plasma–derived products, is one of the five Italian pharmaceutical companies which got EMAS registration. The company has joined an “Environmental Programme” and has thereby assumed specific environmental policy commitments. At the same time, it has drawn up an “Environmental Statement” which – in terms of regulation CE 761/2001
Research project for developing a new plasma derivative for the treatment of Hepatitis C
For the first time in Europe, a project is currently underway in Naples to develop an anti-infective product for Hepatitis C, containing neutralising immunoglobulins directed against specific viral antigens. With the western market estimated at $400 million ($200 million in the United States alone and about $40 million in Italy), it should guarantee a better
New plant in the Kedrion factory: 7 million invested and a 50% increase in production of Factor VIII and Factor IX
The new production department for sterile “Filling and Freeze-Drying of Heat-treated Coagulation Factors” in the Kedrion factory in Bolognana is now in operation. 7 million euros invested and a forecast increase of 50% in the production of Factor VIII and Factor IX which currently represent the 20% of turnover and the asset for the Contract
Kedrion and ProMetic form strategic alliance to develop orphan drugs from plasma
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic’s proprietary manufacturing process, the Plasma Protein Purification System (PPPS). The alliance between the two companies was created to select specific proteins which can be manufactured
Nabi Biopharmaceuticals secures agreement with Kedrion to co-develop and commercialize CIVACIR® in Europe
Nabi Biopharmaceuticals (Nasdaq: NABI – News) announced that it has secured an agreement with Kedrion S.p.A., a global biopharmaceutical company, located in Lucca, Italy. Under the terms of the agreement, Nabi Biopharmaceuticals and Kedrion will pursue a common strategy to develop and commercialize Civacir® [Hepatitis C Immune Globulin (Human)] in Europe and the U.S., with